Drug-induced J point elevation: A marker for genetic risk of sudden death or ECG curiosity?

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 2, 1999, Pages 219-223

  Roden, Dan M ^a   Wilde, Arthur A M ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENCAINIDE; FLECAINIDE; PILSICAINIDE; SODIUM CHANNEL BLOCKING AGENT;

DRUG INDUCED DISEASE; ELECTROCARDIOGRAM; GENETIC RISK; HEART ATRIUM FIBRILLATION; HUMAN; LONG QT SYNDROME; MEDICAL ETHICS; MUTATION; NOTE; PRIORITY JOURNAL; ST SEGMENT ELEVATION; SUDDEN DEATH; SYNDROME;

EID: 0032967694     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00663.x     Document Type: Note

References (30)

1. Brugada P, Brugada J: Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391-1396.
2. Martini B, Nava A, Thiene G, et al: Ventricular fibrillation without apparent heart disease: Description of six cases. Am Heart J 1989;118:1203-1209.
3. Nademanee K, Veerakul G, Nimmannit S, et al: Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997;96:2595-2600.
4. Miyazaki T, Mitamura H, Miyoshi S, et al: Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996;27:1061-1070.
5. 3: A marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97:457-460.
6. Krishnan SC, Josephson ME: ST segment elevation induced by class Ic antiarrhythmic agents: Underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardiovasc Electrophysiol 1998;9:1167-1172.
7. Fujiki A, Usui M, Nagasawa H, et al: ST segment elevation in the right precordial leads induced with class Ic antiarrhythmic drugs: Insight into the mechanism of Brugada syndrome. J Cardiovasc Electrophysiol 1999;10;214-218.
8. Krishnan SC, Antzelevitch C: Sodium channel block produces opposite electrophysiological effects in canine ventricular epicardium and endocardium. Circ Res 1991;69:277-291.
9. Krishnan SC, Antzelevitch C: Flecainide-induced arrhythmia in canine ventricular epicardium: Phase 2 reentry? Circulation 1993;87:562-572.
10. Lukas A, Antzelevitch C: Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia: Role of the transient outward current. Circulation 1993;88:2903-2915.
11. Didiego JM, Sun ZQ, Antzelevitch C: I-TO and action potential notch are smaller in left vs right canine ventricular epicardium. Am J Physiol (Heart Circ Physiol) 1996;40:H548-H561.
12. k, by flecainide and E-4031 in cat ventricular myocytes. Circulation 1990;82:289-293.
13. Matsuo K, Shimizu W, Kurita T, et al: Dynamic changes of 12-lead electrocardiograms in a patient with Brugada-syndrome. J Cardiovasc Electrophysiol 1998;9:508-512.
14. Belhassen B, Shapira I, Shoshani D, et al: Idiopathic ventricular fibrillation: Inducibility and beneficial effects of class I antiarrhythmic agents. Circulation 1987;75:809-816.
15. Chen QY, Kirsch GE, Zhang DM, et al: Genetic basis and molecular mechanism for idiopathic-ventricular fibrillation. Nature 1998;392:293-296.
16. Rook MB, Alshinawi C, Groenewegen WA, et al: Human SCN5A gene mutations alter Na-current kinetics and associate with VF in patients without structural heart disease. (Abstract) Circulation 1998;98:I-468.
17. Kambouris NG, Nuss HB, Johns DC, et al: Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel. Circulation 1998;97:640-644.
18. Wang Q, Shen J, Splawski I, et al: SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80:805-811.
19. Spirito P, Seidman CE, McKenna WJ, et al: The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-785.
20. Roden DM, Lazzara R, Rosen MR, et al, and The SADS Foundation Task Force on LQTS: Multiple mechanisms in the long QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996;94:1996-2012.
21. McNamara DM, Weiss R, Seibel J, et al: Molecular heterogeneity in the Brugada syndrome. (Abstract) Circulation 1998;98:I-456.
22. Donger C, Denjoy I, Berthet M, et al: KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997;96:2778-2781.
23. Priori SG, Napolitano C, Brown AM, et al: The loss of function induced by HERG and KVLQT1 mutations does not correlate with the clinical severity of the long QT syndrome. (Abstract) Circulation 1998;98:I-457.
24. Roden DM: Taking the idio out of idiosyncratic: Predicting torsades de pointes. PACE 1998;21:1029-1034.
25. Napolitano C, Priori SG, Schwartz PJ, et al: Identification of a long QT syndrome molecular defect in drug-induced torsades de pointes. (Abstract) Circulation 1997;96:I-211.
26. Schulze-Bahr E, Haverkamp W, Hordt M, et al: Do mutations in cardiac ion channel genes predispose to drug-induced (acquired) long QT syndrome? (Abstract) Circulation 1997;96:I-211.
27. Kasanuki H, Ohnishi S, Ohtuka M, et al: Idiopathic ventricular fibrillation induced with vagal activity in patiens without obvious heart disease. Circulation 1997;95:2277-2285.
28. Shimoni Y, Spindler AJ, Noble D: The control of calcium current reactivation by catecholamines and acetylchoiine in single guinea-pig ventricular myocytes. Proc R Soc Lond B Biol Sci 1987;230:267-278.
29. Mery PF, Abi-Gerges N, Vandecasteele G, et al: Muscarinic regulation of the L-type calcium current in isolated cardiac myocytes. Life Sci 1997;60:1113-1120.
30. Locati EH, Zareba W, Moss AJ, et al: Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: Findings from the International LQTS Registry. Circulation 1998;97:2237-2244.